vs. 479,161, respectively) [2] . Further, it is estimated that more than 50% of patients with HIV will be over the age of 50 years by 2015 [5] .
Given the longevity achieved with current therapeutic strategies and the increased time patients are on these treatments because of improved efficacy, enhancing the quality of life (QoL) of patients with HIV by reducing symptoms associated with HIV and its treatment has become an important management goal.
Diarrhea remains an important clinical
concern and is associated with reduced QoL in individuals with HIV during cART [6] [7] [8] . For example, diarrhea contributes to nonadherence or justification for switching from a currently successful cART regimen [7, 9] . While the rate of opportunistic infections as a cause of diarrhea has decreased in the era of cART, there has simultaneously been a proportionate increase in the incidence of noninfectious diarrhea, often linked to use of antiretroviral therapy [7, 10] .
Protease inhibitors (PI) and other antiretroviral medications may alter the function of the intestinal epithelial barrier and lead to secretory diarrhea, leaky-flux diarrhea, or both [11, 12] . Detrimental effects of HIV infection itself on the gastrointestinal tract (i.e., HIV enteropathy) constitute another noninfectious cause of diarrhea [13] . In this review, prevalence, etiology, and current nonpharmacologic and pharmacologic management of noninfectious diarrhea in patients with HIV are described. This article is a review and does not contain any new studies with human or animal subjects performed by any of the authors.
Prevalence of Noninfectious Diarrhea
Using observational data to determine prevalence rates is sometimes deemed less valuable than using data from randomized controlled studies. However, evidence exists that with respect to true rates of adverse events (AEs), like noninfectious diarrhea, data from observational studies and randomized controlled trials are comparable [14] . In order to facilitate reading from either viewpoint, this review has separated observational data from data that have been obtained from controlled clinical studies.
Observational Studies
Before the widespread use of cART, up to 70% of patients with HIV reported the development of diarrhea [10, 15] . From 1995 to 1997 [7, 10, [16] [17] [18] , as the use of cART increased to [80% of patients [19] , overall rates of diarrhea decreased but, importantly, the causality changed from infectious to noninfectious [10] . This is reflected in Table 1 [7, 10, [16] [17] [18] . The incidence of opportunistic infections causing diarrhea decreased from 53% to 13%, whereas noninfectious causes of diarrhea increased from 32% to 70% [10] . The predominant cause of noninfectious cases was medicationassociated diarrhea, which increased from 0% in 1995 to 45% in 1997. The medications most commonly used by patients during this period were PIs (e.g., nelfinavir, ritonavir, saquinavir, and indinavir) and a nucleoside reversetranscriptase inhibitor (NRTI; didanosine) [10] .
Today, despite improvement in gastrointestinal tolerability of the newer agents (including the one most recently approved, dolutegravir) [20] , diarrhea remains a common condition in patients with HIV, including those experiencing virologic and immunologic success [7] . Two cohort studies found diarrhea rates ranging from 39% [16] to 60% [17] and, in one instance, the incidence of diarrhea in a population of people with HIV was quadruple the rate reported for a non-HIV population [7] . Considering the influence of the class of cART, patients receiving PIs had a higher incidence of diarrhea compared with those on PI-sparing regimens (38% vs. 17%, respectively) [7] . The impact on patients' lives is best reflected by a 2008 cross-sectional survey of patients with HIV taking cART (n = 953), in which diarrhea was ranked second (63.0%) only to fatigue (70.7%) as the most common medication-related AE [18] .
Randomized Clinical Studies as Cited in Individual cART Component Package Inserts
The FDA does not standardize or mandate the specific manner in which pharmaceutical manufacturers should report diarrhea within the approved prescribing information (also referred to as package inserts). Table 2 outlines the various ways in which these data are presented (by grade, causality, treatment discontinuation, etc.). Package inserts infrequently disseminate incidence rates for all severities of diarrhea. Instead, most only report rates using terms such as ''moderate'' and ''severe'' diarrhea, with some including the actual percentages of patients meeting a particular definition (e.g., [4 loose or watery bowel movements per day). In one example, prescribing information for the non-nucleoside reverse-transcriptase inhibitor (NNRTI) class only reported grade 2 or higher severity of diarrhea using the Division of AIDS grading scale (DIADS) definition [21] , which translated to increase from baseline of 4-6 loose or watery bowel movements per day, poorly reflecting the true incidence of loose stools in persons being prescribed these agents today.
Up to 28% of patients taking today's commonly used antiretroviral therapies deal with [4 loose or watery stools per day (see Table 2 ) [22] . According to prescribing know the difference in rates between arms of the trial, having a better idea of the true incidence that is likely to occur in patients is also important.
Fixed-Dose Combination Antiretroviral
Products Incidence of diarrhea with fixeddose combination, single-tablet regimens appears to be based on the side effect profiles of the component medications or, at times, a compilation of data from various studies involving the coformulated agents and the data used in FDA-approved package inserts.
For instance, in a 48-week phase 3 clinical trial of efavirenz/emtricitabine/tenofovir disoproxil fumarate, diarrhea of any grade was reported in 8% of patients [34] . However, in the prescribing information for this formulation, the incidence of moderate to severe diarrhea is reported as 9% ( Table 2 ). The publication on the phase 3, 48-week, clinical trial of elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate reported an incidence of 22% for diarrhea of any grade [35] . However, the incidence of all grades of diarrhea in the approved labeling is only 12%. This variance in incidence and severity reporting (12% vs. 22%) reinforces the need for individual patients prescribed this combination agent to be assessed by their clinicians for the occurrence of loose stools.
As summarized earlier, clinicians are likely to face challenges when it comes to predicting the true rates of diarrhea occurring in persons taking cART, using only prescribing information. Accordingly, regardless of which combination of antiretroviral therapy is initiated, patients should be counseled to report loose, watery stools or diarrhea to enable their medical providers to determine whether the etiology of the patient's diarrhea is infectious (not covered in this review) or noninfectious.
Etiology of Noninfectious Diarrhea
The etiology of noninfectious diarrhea in patients with HIV is multifactorial and most likely includes (in decreasing order of influence) cART-associated diarrhea; the detrimental effects of HIV on the gastrointestinal tract (i.e., HIV enteropathy); and, infrequently, HIVassociated malignancies and pancreatitis [36] .
cART-Associated Diarrhea There are two primary theoretical mechanisms by which cART may cause diarrhea: damage to the intestinal epithelial barrier, which leads to ''leaky-flux'' diarrhea, and altered secretion of calcium-dependent chloride ions, which causes secretory diarrhea [11, 12, 37] .
Intestinal barrier damage: In in vitro and in vivo studies, PIs induced endoplasmic reticulum stress and activated an unfolded protein response, leading to apoptosis of intestinal cells [38] . Two caveats to these data are (1) the concentrations of PIs used in these studies substantially exceeded those obtained in humans treated with the FDA-approved doses of PIs [6] , and (2) HIV receiving cART [40, 41] .
HIV Enteropathy
HIV enteropathy has been proposed to result from viral infection of gastrointestinal enterocytes, leading to a loss of the intestinal epithelial barrier function of the gastrointestinal mucosa [13, 42, 43] . This loss may manifest as villous atrophy, crypt hyperplasia, and villous blunting, leading to increased permeability [44] . Consequent activation of the gastrointestinal immune system, leading to inflammation, may further trigger barrier degradation. Finally, a welldescribed complication of HIV infection is HIV directly damaging the autonomic nerves of the intestine, leading to faster intestinal transit times [6] .
Implications of Noninfectious Diarrhea in Patients with HIV
Diarrhea is known to complicate the management of patients with HIV by contributing to nonadherence or causing a need for modification of an otherwise virologically and immunologically successful regimen [7, 9] . Especially concerning is when patients independently decide to discontinue cART due to diarrhea. In a retrospective study analyzing first-line antiretroviral therapy discontinuation during a 22-year period (1,861 patient-years of follow up), gastrointestinal symptoms were the most common AEs associated with treatment discontinuation [9] . Switching from one antiretroviral therapy to another is a feasible option, although patients who switch therapy are at an increased risk for reduced QoL [46] . Further, there are a limited number of times for which patients can switch therapies before recycling of antiretroviral agents occur [47] . Therefore, symptomatic management of mild to moderate AEs before switching from a successful antiretroviral regimen may be preferable.
Management of Noninfectious Diarrhea
As a general rule, management of medical conditions begins with lifestyle modification followed by alteration of the offending agent (if considered to be the etiology [49] [50] [51] [52] [53] [54] [55] . This review focused on literature involving patients with HIV, as cART requires special considerations.
Nonpharmacologic and Complementary Alternative Medicine Approaches
Traditional nonpharmacologic agents for the symptomatic treatment of diarrhea in patients with HIV include dietary modifications, use of fiber, and administration or application of other supplements (see Table 3 ) [49, [51] [52] [53] [54] [55] .
Dietary Modification
Unfortunately, for the evidence-driven clinician, scientific data supporting the effectiveness of dietary interventions for managing diarrhea in patients with HIV are sparse. A single clinical study of symptom management in HIVassociated diarrhea (N = 75) using normal foods (i.e., a low-fat, low insoluble fiber, lactose-free, high soluble fiber, and caffeine-free diet) versus a control group without dietary restrictions reported that after 24 weeks, dietary intervention was effective in reducing stool frequency (p = 0.0003) and improving stool consistency (p = 0.0002) [51] . This approach is reasonable and should be encouraged. It is also potentially a beneficial lifestyle modification for patients with HIV, especially those with comorbid conditions of diabetes and obesity.
Bulking Agents
Classified by the FDA as food supplements, psyllium and oat bran are bulking agents. [52, 61] . In a larger placebo-controlled, randomized study, 69 patients with HIV who were also naïve to antiretroviral therapy received treatment with Lactobacilli strains for 25 weeks but reported no significant modification of diarrheal symptoms compared with placebo [62] . At present, the use of probiotics for the treatment of noninfectious diarrhea in patients with HIV (especially those receiving cART) is not supported in the literature. However, the limited body of evidence does not reflect the wide diversity of probiotics available that have yet to be tested and may demonstrate verifiable efficacy in the future. This approach, similar to bulking agents, falls into the unscientifically grounded category of ''unlikely to cause harm'' and seems reasonable if favored by the patient. including HIV-associated forms [64] . Its place within the treatment decision algorithm should be known following completion of ongoing clinical trials.
L-Glutamine
In a randomized, placebo-controlled study of 25 patients with HIV and nelfinavir-induced diarrhea, supplementation with L-glutamine significantly reduced the severity of diarrhea. p\0.01 [53, 65] . However, this approach has not been replicated by others, nor has it been evaluated using cART agents commonly prescribed today. Further data would be beneficial to interpret where L-glutamine fits into the treatment paradigm.
Curcumin
The beneficial effects of curcumin have been reported in the treatment of various disease states. The mechanism of action of curcumin in diarrhea is theorized to be related to its antiinflammatory properties (the reader is referred to Dulbecco and Savarino 2013 [66] for a comprehensive review of this agent and its potential medicinal properties). Curcumin is a naturally occurring hydrophobic phenol extracted from turmeric, which is best known as the primary spice in curry or the yellowing agent for some varieties of mustard. With respect to HIV-associated diarrhea, there is a single clinical study (n = 8) of patients treated with curcumin for a mean of 41 weeks (7/8 patients were receiving cART) [54] . In this case series of eight patients, curcumin therapy 
Acupuncture
The combination of acupuncture and moxibustion (application of heat generated by burning of an herbal mixture containing Artemisia) has been used to address the bowel patterns of patients with HIV; however, evidence for the effectiveness of this therapy is limited [55] . While many patients with HIV may receive acupuncture to alleviate symptoms, it would likely take a clinical research network-generated, peer-reviewed publication describing the antidiarrheal effect of acupuncture and moxibustion to fully inform practicing clinicians and patients alike on this particular use. Until sufficient data are available, this treatment modality cannot be recommended.
Pharmacologic Options
Adsorbents Adsorbents such as bismuth subsalicylate and attapulgite act by adsorbing fluids and compounds to improve stool consistency (see Table 4 ) [67] . This approach for managing HIVassociated noninfectious diarrhea has been considered based on the high degree of success observed in some patients using adsorbents to treat travelers' diarrhea [68, 69] . However, the etiology and pathophysiology of travelers' diarrhea is distinct from that of HIV-associated noninfectious diarrhea, and the success of therapies for travelers' diarrhea has not transferred to the setting of HIV [70] . Clinical evidence for the use of these agents in controlling diarrhea in the HIV population is limited to one randomized, double-blind study that reported that attapulgite was no better than placebo for improving stool consistency or stool frequency in adults with HIV and diarrhea [67, 71] . These agents cannot be recommended for use at this time for the treatment of HIVassociated noninfectious diarrhea.
Antimotility Agents
Oral antimotility agents such as loperamide and diphenoxylate/atropine are opioid derivatives, which increase fecal transit time by decreasing bowel activity and increasing tone in the large intestine. These actions, in turn, provide greater opportunity for the potentially leaky gastrointestinal tract to absorb fluid from the gut [67] .
Loperamide The best evidence for chronic use of loperamide in patients with HIV comes from a study that included concomitant use of [72] . A retrospective study, published in abstract form in 1998 and cited in reviews, indicated that 32% of patients with HIV receiving nelfinavir responded to loperamide treatment for the management of diarrhea [49] .
However, the use of loperamide, particularly for long-term management, may be limited by treatment-related AEs, including drug interactions with antiretroviral therapy [73, 74] . As a P-glycoprotein (P-gp) substrate unable to cross the blood-brain barrier (P-gp efflux pump prevents this translocation), loperamide generally only possesses peripheral opioid activity [75] . Although PIs (as P-gp inhibitors) could increase loperamide levels in the brain, potentially causing respiratory depression [76] , formal evaluation of coadministration of loperamide with ritonavir-boosted tipranavir did not result in any clinically relevant central nervous system opioid effects [75] . Given the substantial clinical history of use of loperamide to treat diarrhea in patients with HIV, despite minimal supporting peer-reviewed evidence, loperamide represents a relatively safe and inexpensive first-line approach.
Diphenoxylate/Atropine Data on the use of diphenoxylate/atropine for the treatment of diarrhea in patients with HIV are sparse. There are anecdotal, non-peer-reviewed reports of low-dose (1-5 mg) diphenoxylate/atropine for the treatment of PI-induced diarrhea. However, in one published trial of six patients previously unresponsive to loperamide therapy, there was no benefit with diphenoxylate/atropine [49] . In addition, as diphenoxylate crosses the bloodbrain barrier at high doses, this potentially leads to dependence and abuse, further discouraging use of this product [73] . As with loperamide, the evidence for use of diphenoxylate/atropine to treat diarrhea in patients with HIV is primarily anecdotal. Despite its long-standing history of availability, this agent should be reserved for patients unresponsive to other options, given its propensity for AEs (including constipation and abuse risk).
Antisecretory Agents
Octreotide and crofelemer are antisecretory agents with peer-reviewed published data showing their efficacy in treating diarrhea in patients with HIV. These agents inhibit secretory processes within the enterocyte, but the mechanism for their effects, safety profiles, and drug-drug and drug-disease interaction potentials vary greatly. [78] . In 1996, Beaugerie et al. [79] reported a profound response from a mean ± SE stool frequency at baseline of 5.7 ± 1.8 to Crofelemer (SP-303) Crofelemer is an FDAapproved, orally administered, minimally absorbed, botanical drug derived from the stem bark latex of the Croton lechleri tree [83] .
Crofelemer is an inhibitor of both the cAMPstimulated CFTR chloride channel and the CaCC; both of these ion channels regulate Cl 
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